Navigation Links
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent
Date:9/24/2010

WASHINGTON, Sept. 24 /PRNewswire/ -- OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

"Completion of enrollment of this study represents a significant milestone as we look to validate the potential for the Combo Stent in a clinical setting," said Al Novak, Chairman and CEO of OrbusNeich.

The primary objective of the prospective, randomized, multicenter study, called REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), is to demonstrate safety and effectiveness of the Combo Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective will be measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure.

Michael Haude, M.D., director of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and one of the trial's principal investigators, added, "The Combo Stent has the potential to bring a unique treatment option to physicians by combining the proven Genous endothelial progenitor cell capture technology with a low dose sirolimus elution. Because the pre-clinical data demonstrate lower neointimal hyperplasia and improved endothelial coverage, we look forward to obtaining clinical confirmation of the results."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, Major Adverse Cardiac Event (MACE) and stent thrombosis rates at 30 days, nine months and one through five years, as well as clinically driven Target Lesion Revascularization (TLR), Target Ves
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... WASHINGTON , July 25, 2014 Cardinal ... innovative community pharmacies as winners of its prestigious Independent ... Business Conference , one of the nation,s largest gatherings ... Competition winners – family-owned pharmacies from Ohio ... Texas – were selected for implementing ...
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... March of Dimes Message: Start Taking a Vitamin with ... Women who take folic acid supplements for at least ... risk of having a premature baby by half, according ... PLOS Medicine.The study links pre-conceptional folate supplementation of at ...
... Results of its Clinical Study of LT-NS001 vs. naproxen ... Logical Therapeutics, Inc (Logical), a biotechnology company focused on ... inflammation, today announced that Peter A. Lankau has been ... the Company,s Board of Directors. Mr. Lankau was ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with a characteristic ... manufactured either through the separation from crude C4 refinery ... olefin (alkene) 1-Butene is a versatile chemical that can ... such as linear light density polyethylene (LLDP), polybutene-1, valeraldehyde, ... is extremely competitive. The market has several market participants ...
(Date:7/27/2014)... Bromine market report defines and segments the Bromine market in ... in European region comprises of four major countries. They are ... a dominant share of Bromine market influences the demand for ... the TOC of the Europe Bromine Market report, to get ... TOC of the Europe Bromine Market report. The report provides ...
(Date:7/27/2014)... As Tylenol lawsuits ( ... forward in federal court, Bernstein Liebhard LLP notes ... the benefits purportedly associated with acetaminophen, the active ... appears in the The Lancet, looked at 1,643 ... were given either acetaminophen or a placebo for ...
(Date:7/27/2014)... 27, 2014 (HealthDay News) -- Couples aren,t more likely ... than the husband, new research finds. The study ... that education levels play a direct role in affecting ... Still, "our results speak against fears that women,s growing ... marital stability," Christine Schwartz, lead author of the study, ...
(Date:7/27/2014)... July 27, 2014 iFitDress.com, a well-known ... latest range of wedding gowns with sleeves . ... elegant items; they are now available with big discounts, ... is true that iFitDress.com is one of the big ... sales representative, the new wedding gowns feature fine craftsmanship ...
Breaking Medicine News(10 mins):Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
... EDAP TMS S.A. (Nasdaq:,EDAP) the global leader ... announces that it has entered into a securities ... buyers,("Investors") pursuant to which the Investors will purchase ... EDAP,s ordinary shares,which will be delivered in the ...
... BOSTON, Oct. 30 Portrayals of bipolar,disorder seem ... news, in movies, and,on television. The November 2007 ... and misunderstandings about this condition., Bipolar disorder ... confused,with other mental illnesses. Because mania is the ...
... was,released today by the Center for Consumer Freedom:, ... the results of a five-year examination of various causes ... expected to recommend,limiting human intake of specific foods, including ... for Consumer Freedom is,available to discuss the implications of ...
... Down syndrome infants on treadmill training for just minutes ... or five months earlier than with only traditional physical ... says. , The study also suggests that infants who ... , Getting infants walking is critical because so ...
... children with dyslexia struggle to read because their ... according to a brain-imaging study published this month ... October 16). The study found that sound training ... correcting the sound processing problem and improving reading. ...
... California will simultaneously open their doors Wednesday to ... cover the,festivities, SAN FRANCISCO, Oct. 30 It,s ... Nurse administrators don,t often,see miniature witches and 3-foot-tall bumblebees, ... 80-year-young ballerinas! But at more,than 150 nursing homes in ...
Cached Medicine News:Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 2Health News:EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies 3Health News:Misconceptions About Bipolar Disorder Explained, From the Harvard Health Letter 2Health News:Treadmill training helps Down syndrome babies walk months earlier 2Health News:Sound training rewires dyslexic children's brains for reading 2Health News:Sound training rewires dyslexic children's brains for reading 3Health News:Halloween Events in the Bay Area Bring Young and Old Together for a Ghoulish Good Time 2
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
This Flex Goggle has a unique wrap around design which fits the contour of the face and brow for optimum coverage. The ratchet style temple hinge allows multiple adjustments in, out, up and down for...
... constructed of extremely durable nylon that exhibits ... The molded wrap around feature provides maximum ... distribute weight evenly over the nose while ... side shields. Also available with adjustable ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
Medicine Products: